Equity
Treasury Stock
AbbVie Treasury Stock increased by 0.0% to $9.15B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 11.5%, from $8.20B to $9.15B. Over 5 years (FY 2020 to FY 2025), Treasury Stock shows an upward trend with a 32.2% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryCapital Allocation
SignalContext dependent
VolatilityModerate
First reportedQ4 2014
Last reportedQ4 2025
How to read this metric
An increase indicates active share buybacks, which can signal management's confidence in the stock or an effort to return capital to shareholders.
Detailed definition
Treasury stock represents the cost of shares that a company has repurchased from the open market and holds in its own tr...
Peer comparison
Standard across all public companies; peers in the pharmaceutical sector often use buybacks to manage earnings per share.
Metric ID:
treasury_stockHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.02B | $3.02B | $3.14B | $4.59B | $4.59B | $4.59B | $4.59B | $6.52B | $6.53B | $6.53B | $6.53B | $7.83B | $7.84B | $7.85B | $8.20B | $9.14B | $9.15B | $9.14B | $9.15B |
| QoQ Change | — | -0.1% | +4.1% | +45.9% | +0.1% | -0.0% | +0.1% | +42.0% | +0.1% | -0.0% | +0.1% | +19.8% | +0.1% | +0.1% | +4.5% | +11.4% | +0.1% | -0.0% | +0.0% |
| YoY Change | — | — | — | — | +51.9% | +52.0% | +46.2% | +42.3% | +42.2% | +42.2% | +42.2% | +20.0% | +20.1% | +20.3% | +25.5% | +16.7% | +16.7% | +16.5% | +11.5% |
Range$3.02B – $9.15B
CAGR+27.9%
Avg YoY Growth+31.1%
Median YoY Growth+25.5%
Treasury Stock at Other Companies
Frequently Asked Questions
- What is AbbVie's treasury stock?
- AbbVie (ABBV) reported treasury stock of $9.15B in Q4 2025.
- How has AbbVie's treasury stock changed year-over-year?
- AbbVie's treasury stock increased by 11.5% year-over-year, from $8.20B to $9.15B.
- What is the long-term trend for AbbVie's treasury stock?
- Over 5 years (2020 to 2025), AbbVie's treasury stock has grown at a 32.2% compound annual growth rate (CAGR), from $2.26B to $9.15B.
- What does treasury stock mean?
- The value of shares a company has bought back from the market.